keynote-355: hrqol unaffected by the addition of pembrolizumab to chemotherapy for tnbc
Published 2 years ago • 204 plays • Length 1:30Download video MP4
Download video MP3
Similar videos
-
4:49
keynote-355: pembro chemo in triple-negative breast cancer
-
2:07
keynote-355: pembrolizumab in triple-negative breast cancer
-
4:11
immunotherapy for tnbc: impassion130 & keynote-355
-
4:53
chemoimmunotherapy in tnbc: the keynote-355 trial
-
12:45
keynote-355: first-line pembrolizumab plus chemotherapy for metastatic triple-negative breast ca...
-
2:00
pembrolizumab plus chemotherapy show efficacy for tnbc in keynote-355
-
2:24
keynote-355: pembrolizumab in triple-negative breast cancer
-
2:34
esmo 2021 breast cancer highlights: tulip and keynote-355
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
0:53
keynote-522 demonstrates potential for immunotherapy in triple-negative breast cancer
-
4:54
hope rugo, md, shares the design and outcomes of keynote-355 presented at sabcs 2020
-
3:07
highlights from sabcs 2021: t-dxd, keynote-355, pada-1 & emerald
-
1:42
hope rugo, md, offers key takeaways for physicians regarding keynote-355
-
1:14
the importance of a biomarker-directed approach in triple-negative breast cancer
-
1:35
longer overall survival in metastatic tnbc with pembrolizumab - medpage today
-
0:50
update on keynote 522, the current standard of care for triple negative breast cancer.
-
13:03
early tnbc - pembrolizumab chemotherapy: pathologic complete response in key subgroups
-
1:01
chemo-immunotherapy for tnbc
-
6:16
latest on immunotherapy in triple-negative breast cancer - medpage today